Thyrocare Technologies share price today

Thyrocare Technologies Ltd's share price was ₹495.50 at the close on 4 November 2026. It has been rising for 24 weeks. That is 0.6% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹351 and ₹624, and at that close it sat 53% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Thyrocare Technologies Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 4 weeks running.

Over the last 11 years the share price moved +138% while the NIFTY 500 moved +231%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 9 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

9 points in one quarter.

1. Profit fell in the September 2026 quarter

   Profit was ₹15 crore, -68.7% on a year earlier (₹48 crore), after 10 quarters of growth.

   Why: Profit fell because the company booked a Rs45 crore accounting charge in its consolidated results linked to the sale of its radiology business, Nueclear. That charge did not involve cash leaving the business.

   Next results: check whether shareholders approve the Nueclear sale and it closes, and how the business is treated in the accounts.

   From the earnings call on 29 Oct 2026.

2. Foreign funds (FIIs) raised their stake for 6 quarters in a row

   From 2.4% to 9.4% of the company by the September 2026 quarter.

3. Promoters cut their stake by 9.9 points in one quarter

   From 60.9% to 51% in the September 2026 quarter.

For July to September 2026 (the quarter ended 30 September 2026), Thyrocare Technologies reported revenue of ₹271 crore, up 24.9% from ₹217 crore a year earlier, and a profit of ₹15.0 crore, down 68.7% from ₹48.0 crore.

Thyrocare Technologies results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Thyrocare Technologies' management discussed these results on a call held on 29 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Thyrocare Technologies closed at ₹495.50 on 4 November 2026, up 6.9% from ₹463.70 a year earlier (7 November 2025) and up 28.8% over five years. Its highest weekly close since May 2016 was ₹624.05 on 14 August 2026.

Thyrocare Technologies share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

555 weekly closes from 13 May 2016 to 4 November 2026.

4 Nov 2026: Thyrocare Technologies closed at ₹495.50, up 8.6% on the week and down 7.1% on the month. 29 Oct 2026: Thyrocare Technologies held its results call for July to September 2026. Management guided: FY27 revenue growth seen in early-20s percent.

Earlier

• Results for July to September 2026: Revenue up 24.9% and profit down 68.7% on a year earlier.
• Our read, 22 Aug 2026: The pathology network is converting volume and channel expansion into earnings, while specialty diagnostics remains an option whose delivery timetable has widened.
• 23 Jun 2026: ex-date for a dividend of ₹7 a share.
• 28 Nov 2025: Bonus issue: 2 new shares for every 1 held (ex-date).

Our read of the business

Latest quarter: Revenue advanced while operating margin eased from the March quarter.

Our read after the latest results, written 22 August 2026.

Thyrocare Technologies paid ₹7 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 1.41% at the ₹495.50 close on 4 November 2026. The last was a dividend of ₹7 a share, ex-date 23 June 2026.

Thyrocare Technologies dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Thyrocare Technologies Ltd paid out 137% of its profit as dividends in FY26, and it paid a dividend in each of its last 12 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 29 October 2026, Thyrocare Technologies' management guided: FY27 revenue growth seen in early-20s percent.

“I would say that a long-term guidance of about 31% to 31.5%, where we are funding all these investments for growth, is what I would anchor on, and not above that.”Rahul Guha, MD and CEO, on the call for July to September 2026

What management guided

• Long-term operating profit around 31 to 31.5 percent versus about 32 percent last year and 32.6 percent in H1 funding growth spending.
• Franchise adds to surpass 1,500 this year; 1,500-2,000 yearly to 20,000-25,000 in 5 years; Q3 soft, Q4 normal; ARPF ₹1.2L range-bound.
• Specialty to reach 10-15 percent of revenue in 3-5 years on allergy and genomics scale.
• Pregnancy kit not EPS-accretive for 3 quarters; Q3 brand spend around ₹3 crore; category guidance next fiscal.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 29 October 2026.

What is changing at Thyrocare Technologies, from the latest results and calls: franchise-network expansion, specialty diagnostics commercialization and operating leverage from pathology volumes.

• Franchise-network expansion. The active franchise base and scheduled net additions can extend pathology reach, subject to retention of newly added outlets. ⚠ estimate
• Operating leverage from pathology volumes. Revenue growth has outpaced the rise in the fixed operating base, allowing profit to grow faster than sales in recent periods. ⚠ estimate
• Partnership and backend diagnostics channel. Partnership revenue is expanding alongside insurance and healthtech integrations, giving the company a second volume route beyond franchises. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.

Our read after the latest results, written 22 August 2026.

The thesis breaks if revenue growth falls below the stated franchise-led framework while operating margin remains below the recent corridor for two reported quarters, because that would show that the existing network is no longer converting volume into operating leverage.

Each change stops working if

• Franchise-network expansion: New additions churn faster than the planned net schedule or the next reported quarter misses the stated addition goal.
• Specialty diagnostics commercialization: Physician-led specialty volumes do not become measurable while the goal timetable continues to move outward.
• Operating leverage from pathology volumes: Operating margin falls below the comparable-period level while revenue growth remains positive.
• Partnership and backend diagnostics channel: Partnership growth slows without a disclosed comparison-base or pricing explanation.

The main risks

• Management goal credibility: The specialty timetable widened after earlier radiology and Tanzania expectations were not delivered as first framed. ⚠ estimate
• Margin and reagent-cost pressure: The latest operating margin was below the March quarter and management has linked margin protection to volume scale. ✓ fact
• Radiology and nuclear-business execution: Radiology revenue was down year on year and the nuclear business partner process had no definitive customer at the latest call. ✓ fact

Our read after the latest results, written 22 August 2026.

When Thyrocare Technologies reports October to December 2026, these are the check that show whether the story is still on course. First: Nueclear shareholder approval and SPA execution - check closure and held-for-sale status next quarter.

Thyrocare Technologies is not on any of our India lists this week.

Thyrocare Technologies Ltd earned ₹15.0 Cr of net profit in the Sep 2026 quarter, −68.8% on the same quarter a year earlier. Full-year FY26 profit was ₹163 Cr. Over 10 years profit has grown 12.1% a year on average. That is 5.5% of the quarter's revenue. The same quarter a year earlier earned ₹48.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹163 Cr (+79.1% on the year before).

Why profit moved: revenue changed +24.9% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +33.9% and revenue +21.8%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Thyrocare Technologies Ltd reported ₹271 Cr of revenue in the Sep 2026 quarter, +24.9% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 13.1% a year on average. The last full year, FY26, came in at ₹829 Cr.

Revenue is everything the company billed its customers in the period.

Why this happened. The value-chain climb applies because the company is adding higher-complexity tests to an existing pathology platform. Central-lab capex is largely completed, but physician adoption and volume are the gating variables. The latest timetable widened, so specialty remains optionality rather than a base-year earnings assumption.

The last four reported quarters add to ₹931 Cr.

FY26 revenue was ₹829 Cr, +20.7% on the year before.

Recent pace: the last four quarters grew +21.8% on average, against 13.1% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +22.0%, against +22.2% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +12.6%, against +32.1% a year (rolling over).

Thyrocare Technologies Ltd's operating margin was 33.0% in the Sep 2026 quarter, about the same as the same quarter a year ago. Across 12 years it has been between 23.0% and 41.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why this happened. Management reported the active franchise base at the latest quarter and set a staged plan for net additions across the year. This supports volume growth through distribution rather than a new laboratory build. The off-switch is churn among the early additions or a failure to meet the next quarterly addition goal.

In the latest quarter it moved +0.0 percentage points on the same quarter a year ago.

Why the margin moved: operating margin changed +0.0 percentage points on the year while gross margin changed +1.9 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 177% of Thyrocare Technologies Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹213 Cr of operating cash against ₹163 Cr of profit. After ₹68.0 Cr of spending on assets, ₹145 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 177% of profit came in as cash: the cash cycle got 25 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets.

Thyrocare Technologies Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 4 days in FY26, down from 29 days in FY21. It spent ₹185 Cr on assets over the last 3 years. Customers take 33 days to pay, and stock sits for 81 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹829 Cr, each day of that cycle ties up about ₹2.3 Cr, so roughly ₹9.0 Cr is tied up in the business at any time.

FY26: customers took 33 days to pay and stock sat for 81 days, about 2.7 months of sales sitting as stock, for a full cycle of 4 days, shorter than FY21's 29.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 81 days. Customers pay about 33 days after that. Suppliers are paid at 109 days. Together that makes the 4-day cycle.

Spending on assets: ₹185 Cr over the last 3 years, against ₹161 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹3.0 Cr (FY26): assets paid for that are not earning yet.

In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean.

Thyrocare Technologies Ltd's P/E is 45.1×, in the middle of its own history: higher than 47% of past readings. Its usual P/E (the middle reading) is 47.4×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹9.06.